Who is sponsoring NCT01517373?

NCT01517373 is sponsored by Pfizer.

What condition does NCT01517373 study?

NCT01517373 studies Diabetes Mellitus, Type 2.

What drugs are being tested in NCT01517373?

Interventions: Placebo, PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg, Glimepiride.

What is the status of NCT01517373?

NCT01517373 is currently COMPLETED.

Last reviewed 2016-12-06 · How we verify

A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety And Efficacy Of Pf-04937319 And Glimepiride In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin

NCT01517373 Phase 2 COMPLETED Results posted

This is a study to understand efficacy and safety of investigational agent (PF-04937319) compared to approved agent (glimepiride) in patients with diabetes on metformin

Details

Lead sponsor	Pfizer
Phase	Phase 2
Status	COMPLETED
Enrolment	304
Start date	2012-02
Completion	2013-01

Conditions

Diabetes Mellitus, Type 2

Interventions

Placebo
PF-04937319 10 mg
PF-04937319 50 mg
PF-04937319 100 mg
Glimepiride

Primary outcomes

Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12 — Baseline (Day 1), Week 12
HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as less than 6.5 percent by the study-specific central laboratory used. Change from baseline in percentage of HbA1C was reported.

Countries

United States, Bulgaria, Canada, Hungary, India, Slovakia, Taiwan